- Home
- SLRX vs SCNI Comparison
SLRX vs SCNI Comparison
Compare SLRX & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLRX
- SCNI
- Stock Information
- Founded
- SLRX N/A
- SCNI 2003
- Country
- SLRX United States
- SCNI Israel
- Employees
- SLRX N/A
- SCNI N/A
- Industry
- SLRX Biotechnology: Pharmaceutical Preparations
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLRX Health Care
- SCNI Health Care
- Exchange
- SLRX Nasdaq
- SCNI Nasdaq
- Market Cap
- SLRX 1.8M
- SCNI 1.9M
- IPO Year
- SLRX N/A
- SCNI N/A
- Fundamental
- Price
- SLRX $0.72
- SCNI $2.55
- Analyst Decision
- SLRX
- SCNI
- Analyst Count
- SLRX 0
- SCNI 0
- Target Price
- SLRX N/A
- SCNI N/A
- AVG Volume (30 Days)
- SLRX 23.3K
- SCNI 1.1M
- Earning Date
- SLRX 05-14-2025
- SCNI 07-01-2025
- Dividend Yield
- SLRX N/A
- SCNI N/A
- EPS Growth
- SLRX N/A
- SCNI N/A
- EPS
- SLRX N/A
- SCNI N/A
- Revenue
- SLRX N/A
- SCNI $658,000.00
- Revenue This Year
- SLRX N/A
- SCNI N/A
- Revenue Next Year
- SLRX N/A
- SCNI N/A
- P/E Ratio
- SLRX N/A
- SCNI N/A
- Revenue Growth
- SLRX N/A
- SCNI N/A
- 52 Week Low
- SLRX $0.45
- SCNI $1.90
- 52 Week High
- SLRX $7.20
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- SLRX 41.78
- SCNI 46.70
- Support Level
- SLRX $0.68
- SCNI $2.32
- Resistance Level
- SLRX $0.80
- SCNI $6.18
- Average True Range (ATR)
- SLRX 0.04
- SCNI 0.41
- MACD
- SLRX -0.01
- SCNI -0.01
- Stochastic Oscillator
- SLRX 8.93
- SCNI 8.10
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.